As marked overexpression of HIF-1α was visualized in CML bone marrow patients, the HIF-1α inhibitor 2-ME2 was then employed to treat K562 cells thereby evaluating responses of HIF-1α and the downstream target gene. This evidence concerns the gene HIF1A and chronic myelogenous leukemia, BCR-ABL1 positive.